Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Agile Therapeutics Inc (NQ: AGRX )

2.390 +0.090 (+3.91%)
Streaming Delayed Price Updated: 2:04 PM EST, Dec 7, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Agile Therapeutics Inc

< Previous 1 2 Next >
Agile Therapeutics Posts Growth In Third Quarter Results, Reiterates Confidence In Target of $25M Net Revenue, Positive Cash Flow In 2024
Via ACCESSWIRE
Agile Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
From Agile Therapeutics, Inc.
Via GlobeNewswire
Agile Therapeutics to Report Third Quarter 2023 Financial Results and Provide Business Update on Thursday, November 9, 2023
From Agile Therapeutics, Inc.
Via GlobeNewswire
Agile Therapeutics Reports an Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4)
From Agile Therapeutics, Inc.
Via GlobeNewswire
Agile Therapeutics (NASDAQ: AGRX) Upgraded To “Buy” Rating By Analysts At Maxim Group
Via ACCESSWIRE
Agile Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
From Agile Therapeutics, Inc.
Via GlobeNewswire
Agile Says It's On Track To Hit $25-$30 Million Net Annual Revenue After A Strong Performance In Its Second Quarter
Via ACCESSWIRE
Agile Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
From Agile Therapeutics, Inc.
Via GlobeNewswire
Agile Therapeutics to Report Second Quarter 2023 Financial Results and Provide Business Plan Updates on Wednesday, August 9, 2023
Live Conference Call and Webcast at 8:30 a.m. ET 
From Agile Therapeutics, Inc.
Via GlobeNewswire
This Reproductive Health Company's Weekly Contraceptive Patch Can Reach Millions of Women Thanks to a Partnership With Afaxys
Via ACCESSWIRE
Agile Therapeutics Partners With Telehealth Platforms To Expand Access To Weekly Birth Control Patch To Millions Of Women
Via ACCESSWIRE
Agile Sees Renewed Hope For Even Broader Adoption Of Its Weekly Birth Control Patch After Biden’s Latest Executive Order Expanding Contraceptive Coverage
Via ACCESSWIRE
H.C. Wainwright Reiterates Buy Rating For Agile Therapeutics (NASDAQ: AGRX), Citing Growing Demand For Twirla, A Weekly Low Dose Birth Control Patch
Via ACCESSWIRE
This Women's Healthcare Company Raised $7.5 Million In A Public Offering And Says It's Targeting $25 To $30 Million Net Revenue By End Of 2023
Via ACCESSWIRE
Agile Therapeutics Expects Its Innovative Once-A-Week Birth Control Patch To Drive Revenues Of $25-30 Million In 2023 - What Is The Hype All About?
Via ACCESSWIRE
The Overturning of Roe v. Wade Has Changed the Landscape of Birth Control; Smaller Companies are now an Integral Part of Care
Via ACCESSWIRE
Agile Therapeutics Announces the Availability of Twirla® to MMCAP Infuse Members
From Agile Therapeutics, Inc.
Via GlobeNewswire
Agile Therapeutics Commends the Biden Administration’s Commitment to Strengthening Access to Affordable, High-Quality Contraception and Family Planning Services
From Agile Therapeutics, Inc.
Via GlobeNewswire
Agile Therapeutics Announces the Availability of Twirla® through FPA Women’s Health
From Agile Therapeutics, Inc.
Via GlobeNewswire
Agile Therapeutics Announces New Agreement with vitaCare® Prescription Services to Improve Access to Twirla®
From Agile Therapeutics, Inc.
Via GlobeNewswire
Agile Therapeutics Announces Closing of $7.5 Million Public Offering
From Agile Therapeutics, Inc.
Via GlobeNewswire
Agile Therapeutics Announces Pricing of $7.5 Million Public Offering
From Agile Therapeutics, Inc.
Via GlobeNewswire
Agile Therapeutics Reports First Quarter 2023 Financial Results And Provides Corporate Update
From Agile Therapeutics, Inc.
Via GlobeNewswire
Agile Therapeutics to Report First Quarter 2023 Financial Results and Provide Business Update on Thursday, May 11, 2023
Live Conference Call and Webcast at 4:30 p.m. ET 
From Agile Therapeutics, Inc.
Via GlobeNewswire
Agile Therapeutics Announces Preliminary Expectations for First Quarter 2023
From Agile Therapeutics, Inc.
Via GlobeNewswire
Agile Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement
From Agile Therapeutics, Inc.
Via GlobeNewswire
Agile Therapeutics Announces 1-For-50 Reverse Stock Split
From Agile Therapeutics, Inc.
Via GlobeNewswire
Agile Therapeutics Reports Fourth Quarter & Full Year 2022 Financial Results and Provides Corporate Update
From Agile Therapeutics, Inc.
Via GlobeNewswire
Agile Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on Wednesday, March 22, 2023
Live Conference Call and Webcast at 4:30 p.m. ET 
From Agile Therapeutics, Inc.
Via GlobeNewswire
Agile Therapeutics Granted 180-Day Extension by Nasdaq to Meet the Minimum Bid Price Requirement
From Agile Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.